Teva Pharmaceutical will pay $1.2 billion to settle US antitrust charges in a long-running “pay for delay” case involving Cephalon, which Teva acquired in 2012, the Federal Trade Commission says.
Israel-based Teva, the world’s largest generic drug manufacturer, agrees to make the money available to compensate buyers, including drug wholesalers, pharmacies and insurers, who overpaid for Cephalon’s blockbuster sleep-disorder drug Provigil because of that company’s illegal conduct.
Under the settlement, Teva also agrees to a prohibition in all of its US operations on the type of anticompetitive patent settlements that Cephalon used to artificially inflate the price of Provigil, according to the FTC.
The Jerusalem office of the Israeli drug company Teva Pharmaceuticals (photo credit: Yonatan Sindel/Flash90)
The settlement stems from a 2008 FTC lawsuit against Cephalon alleging that the company unlawfully protected its monopoly on prescription drug Provigil from competition through so called “reverse-payment” deals with four generic drugmakers in 2005-2006.
— AFP
Your next read: ToI Editors' Picks
LIMITED TIME OFFER: Join The Times of Israel Community today and you'll receive a physical book of your choice, carefully curated by our editors.
Choose between two must-reads: When We See You Again by Rachel Goldberg-Polin, a searing portrait of a mother’s grief and strength following unthinkable tragedy;
Or Out of the Sky: Heroism and Rebirth in Nazi Europe by Matti Friedman, the gripping and surprising tale of a forgotten moment during World War II.
As a Community member, you’ll also enjoy our DocuNation series of outstanding Israeli documentary films, an ad-free experience of our site and podcasts, commenting privileges, and more.
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we started the Times of Israel - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
Thank you, David Horovitz, Founding Editor of The Times of Israel